mRESVIA™ (respiratory syncytial virus vaccine) – Expanded indication
June 12, 2025 - Moderna announced the FDA approval of mRESVIA (respiratory syncytial virus vaccine), for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
Top